UPDATE: Morgan Stanley Raises PT on Gilead Sciences Following AlphaWise Survey

In a report published Tuesday, Morgan Stanley analyst Matthew Harrison reiterated an Equal-Weight rating on

, and raised the price target from $81.00 to $100.00. In the report, Morgan Stanley noted, “Our avg. price/patient for US HCV rises ~15%, offset by ~5% cut in total patients (pts) treated in 2015 (~50% Y/Y incr), resulting in modest US HCV sales hikes. Our EU sales are now ~$5.5B in both 2015/2016E, up from ~$3.5B/~$4B.With 70-80% of 2014E ~$2B in EU sales coming from Germany, we expect contributions from France/Italy/Spain & the UK to beat least 50% of the German run-rate, suggesting >$4.5B in 2015E EU sales.” Gilead Sciences closed on Monday at $105.56.